Aldeyra Therapeutics, Inc. (ALDX)
1.48
0.00 (0.00%)
USD |
NASDAQ |
Sep 04, 16:00
1.48
0.00 (0.00%)
After-Hours: 20:00
Aldeyra Therapeutics SG&A Expense (TTM) : 8.438M for June 30, 2026
SG&A Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 8.438M |
| March 31, 2026 | 7.736M |
| December 31, 2025 | 9.602M |
| September 30, 2025 | 9.186M |
| June 30, 2025 | 10.31M |
| March 31, 2025 | 11.69M |
| December 31, 2024 | 11.89M |
| September 30, 2024 | 11.74M |
| June 30, 2024 | 10.64M |
| March 31, 2024 | 10.98M |
| December 31, 2023 | 13.34M |
| September 30, 2023 | 16.27M |
| June 30, 2023 | 16.93M |
| March 31, 2023 | 16.69M |
| December 31, 2022 | 15.37M |
| September 30, 2022 | 13.20M |
| June 30, 2022 | 12.50M |
| March 31, 2022 | 12.43M |
| December 31, 2021 | 11.28M |
| September 30, 2021 | 11.23M |
| June 30, 2021 | 10.93M |
| March 31, 2021 | 10.09M |
| December 31, 2020 | 9.986M |
| September 30, 2020 | 10.69M |
| June 30, 2020 | 11.28M |
| Date | Value |
|---|---|
| March 31, 2020 | 12.17M |
| December 31, 2019 | 12.15M |
| September 30, 2019 | 11.49M |
| June 30, 2019 | 11.71M |
| March 31, 2019 | 10.97M |
| December 31, 2018 | 9.876M |
| September 30, 2018 | 8.832M |
| June 30, 2018 | 7.242M |
| March 31, 2018 | 6.350M |
| December 31, 2017 | 6.186M |
| September 30, 2017 | 5.890M |
| June 30, 2017 | 5.811M |
| March 31, 2017 | 5.792M |
| December 31, 2016 | 5.520M |
| September 30, 2016 | 5.541M |
| June 30, 2016 | 5.406M |
| March 31, 2016 | 4.898M |
| December 31, 2015 | 4.415M |
| September 30, 2015 | 4.196M |
| June 30, 2015 | 3.707M |
| March 31, 2015 | 3.734M |
| December 31, 2014 | 3.563M |
| September 30, 2014 | 3.388M |
| June 30, 2014 | 2.616M |
| March 31, 2014 | 1.633M |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 172.57M |
| Oncolytics Biotech, Inc. | 16.62M |
| Sangamo Therapeutics, Inc. | 31.64M |
| Sarepta Therapeutics, Inc. | 436.74M |
| Anixa Biosciences, Inc. | 6.118M |